Akita University Hospital

Akitashi, Akita 010-8543

0 studies enrolling now · 3 studies all time

What they study most

Advanced Malignancies, Esophageal Squamous Cell Carcinoma (ESCC)

Studies at this site

• Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies — Completed
• A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma — Completed
• A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma — Completed